Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 227, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2021.113951
Keywords
Indole-based ATX inhibitors; Carbamate/urea linker; Computational analysis; PK; Antifibrosis
Categories
Funding
- National Natural Science Foundation of China [81872751, 82104003]
- Liao Ning Revitalization Talents Program [XLYC2002115]
- Key R&D Plan of Liaoning Province in 2020 [2020020215-JH2/103]
Ask authors/readers for more resources
Pharmacological targeting of the ATX/LPA axis has shown promising disease management benefits. New indole-based carbamate derivatives were synthesized, with compound 4 identified as the most potent ATX inhibitor and compound 30 showing improved pharmacokinetic properties and anti-fibrosis effects.
In recent decades, pharmacological targeting of the autotaxin (ATX)/lysophosphatidic acid (LPA) axis accounted for excellent disease management benefits. Herein, to extend the scope of structure-activity relationships (SARs), fifteen indole-based carbamate derivatives (1-15) were prepared to evaluate the ATX inhibitory potency. Among them, compound 4 bearing morpholine moiety was identified as the optimal ATX inhibitor (0.41 nM), superior to the positive control GLPG1690 (2.90 nM). To resolve the intractable issue of poor pharmacokinetic (PK) property, urea moiety was introduced as a surrogate of carbamate which furnished compounds 16-30. The dedicated modification identified the diethanol-amine entity 30 with satisfactory water solubility and PK profiles with a minimum sacrifice of ATX inhibition (2.17 nM). The most promising candidate 30 was evaluated for anti-fibrosis effect in a bleomycin challenged mice lung fibrosis model. Upon treatment with 30, the in vivo ATX activity in both lung homogenate and broncheoalveolar fluid (BALF) sample was significantly down-regulated. Furthermore, the gene expression of pro-fibrotic cytokines transforming growth factor-beta (TGF-beta), interleukin- 6 (IL-6) and tumor necrosis factor-alpha (TNIF-alpha) in lung tissue was reduced to normal level. Collectively, the promising biological effects may advocate potential application of 30 in fibrosis relevant diseases. (C) 2021 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available